4-(2-chlorophenyl)-2-ethyl-6-(2-indolecarboxamido)-9-propyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine | 123677-21-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 4-(2-chlorophenyl)-2-ethyl-6-(2-indolecarboxamido)-9-propyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
• 英文别名: N-[7-(2-chlorophenyl)-4-ethyl-13-propyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]-1H-indole-2-carboxamide
• CAS: 123677-21-4
• 化学式: C₂₈H₂₅ClN₆OS
• 分子量: 529.065
• InChiKey: XSMBOABOOAJVMZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  37
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  116
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• THIENODIAZEPINE COMPOUNDS AND THEIR MEDICINAL USE
  申请人：Yoshitomi Pharmaceutical Industries, Ltd.

  公开号：EP0348523A1

  公开（公告）日：1990-01-03

  Thienodiazepine compounds represented by general formula (I) (wherein R1 and R2 may be the same or different and each represents hydrogen, halogen, alkyl or aralkyl or, when taken together, R1 and R2 form a ring, R3 represents oxygen, R4 represents hydrogen, alkyl, alkenyl or -(CH2)mCOOR6 (wherein R6 represents hydrogen, alkyl, alkenyl or aralkyl, and m represents an integer of 1 to 6), or R3 and R4 are bound to each other to form a group represented by = N- N = C(R5)- (wherein R5 represents hydrogen, alkyl. alkenyl, aralkyl or -(CH2)n; COOR7 (wherein R7 represents hydrogen, alkyl, alkenyl or aralkyl, and n represents an integer of 1 to 6)), Ar and X may be the same or different and each represents aryl or heteroaryl, and p represents 0 or an integer of 1 to 6), salts thereof, and their medicinal use are disclosed. These compounds exhibit an antagonistic effect against cholecystokinin and gastrin and show a persistent action of depressing pancreatic enzymes and secretion of gastric acid, thus being useful as agents acting on central and peripheral nerves and agents for prophylaxis or treatment of pancreatic trouble or gastroenteric ulcer.

  通式(I)代表的噻二氮卓化合物（其中R1和R2可以相同或不同，各自代表氢、卤素、烷基或芳烷基，或者当R1和R2结合在一起时，形成一个环，R3代表氧，R4代表氢、烷基、烯基或-(CH2)mCOOR6（其中R6代表氢、烷基、烯基或芳烷基，m代表1至6的整数），或者R3和R4相互结合形成一个由= N- N = C(R5)-代表的基团（其中R5代表氢、烷基、烯基、芳烷基或-( )n；COOR7（其中R7代表氢、烷基、烯基或芳烷基，n代表1至6的整数）），R3代表氧，R4代表氢、烷基、烯基或-( )mCOOR6（其中R6代表氢、烷基、烯基或芳烷基，m代表1至6的整数）。其中 R7 代表氢、烷基、烯基或芳基，n 代表 1 至 6 的整数），Ar 和 X 可以相同或不同，各自代表芳基或杂芳基，p 代表 0 或 1 至 6 的整数）所代表的基团、其盐及其药用用途均已公开。这些化合物显示出对胆囊收缩素和胃泌素的拮抗作用，并显示出抑制胰酶和胃酸分泌的持续作用，因此可用作作用于中枢神经和外周神经的制剂以及预防或治疗胰腺疾病或胃肠溃疡的制剂。
• Central cholecystokinin antagonists having pharmaceutical activity
  申请人：MERCK SHARP & DOHME LTD.

  公开号：EP0729752A2

  公开（公告）日：1996-09-04

  Pharmaceutical compositions and methods of using CCK-ligands as antipsychotic, antianxiety, and agents useful in treatment or prevention of withdrawal symptoms caused by withdrawal of chronic or long-term use of diazepam, alcohol, cocaine, or nicotine, and antianxiety agents are described.

  描述了使用 CCK 配体作为抗精神病药、抗焦虑药和治疗或预防因长期或长期使用地西泮、酒精、可卡因或尼古丁以及抗焦虑药而引起的戒断症状的药物组合物和方法。
• US4992437A
  申请人：——

  公开号：US4992437A

  公开（公告）日：1991-02-12